Changing the Tone of Clinical Study Design in the Cannabis Industry

Changing the Tone of Clinical Study Design in the Cannabis Industry Publisher

Antony JM¹ ; Mcdonald AC¹ ; Noorbhaksh F² ; Guthrie N¹ ; Evans M¹

Source: Translational Neuroscience Published:2020

Abstract

Cannabis (also known as marijuana) is the most frequently used psychoactive substance globally. Cannabis exerts therapeutic functions for many indications and has vast potential as a health and wellness product. Advances in our understanding of the composition and pharmacological properties of cannabis have revealed interactions between cannabis, an individuals' circadian rhythms and and their endocannabinoid signaling. Exogenously administered cannabinoids can bidirectionally entrain central and peripheral clocks that comprise circadian rhythms, and malfunctions in the endocannabinoid system are reported to impact neurological processes. Therefore, it is necessary to account for the circadian rhythm when designing clinical trials examining the pharmacological properties of cannabis-based products for health and wellness to limit its potential confounding impact on results. Consideration of the entrainment capabilities of the endocannabinoid system is warranted when designing clinical trials. © 2020 Joseph Antony, et al. published by De Gruyter 2020.

Related Docs

View other Related Docs

1. Cannabinoids and Sleep-Wake Cycle: The Potential Role of Serotonin, Behavioural Brain Research (2021)

2. Therapeutic Attributes of Endocannabinoid System Against Neuro-Inflammatory Autoimmune Disorders, Molecules (2021)

3. Therapeutic Potential of Cannabinoids in Counteracting Chemotherapy-Induced Adverse Effects: An Exploratory Review, Phytotherapy Research (2015)

Experts (# of related papers)

View all Related Experts

Mohammad Abdollahi (2)

Seyed Mojtaba Daghighi (1)

Style	Citing Format
MLA	Antony JM, et al.. "Changing the Tone of Clinical Study Design in the Cannabis Industry." Translational Neuroscience, vol. 11, no. 1, 2020, pp. 4-9.
APA	Antony JM, Mcdonald AC, Noorbhaksh F, Guthrie N, Evans M (2020). Changing the Tone of Clinical Study Design in the Cannabis Industry. Translational Neuroscience, 11(1), 4-9.
Chicago	Antony JM, Mcdonald AC, Noorbhaksh F, Guthrie N, Evans M. "Changing the Tone of Clinical Study Design in the Cannabis Industry." Translational Neuroscience 11, no. 1 (2020): 4-9.
Harvard	Antony JM et al. (2020) 'Changing the Tone of Clinical Study Design in the Cannabis Industry', Translational Neuroscience, 11(1), pp. 4-9.
Vancouver	Antony JM, Mcdonald AC, Noorbhaksh F, Guthrie N, Evans M. Changing the Tone of Clinical Study Design in the Cannabis Industry. Translational Neuroscience. 2020;11(1):4-9.
BibTex	@article{ author = {Antony JM and Mcdonald AC and Noorbhaksh F and Guthrie N and Evans M}, title = {Changing the Tone of Clinical Study Design in the Cannabis Industry}, journal = {Translational Neuroscience}, volume = {11}, number = {1}, pages = {4-9}, year = {2020} }
RIS	TY - JOUR AU - Antony JM AU - Mcdonald AC AU - Noorbhaksh F AU - Guthrie N AU - Evans M TI - Changing the Tone of Clinical Study Design in the Cannabis Industry JO - Translational Neuroscience VL - 11 IS - 1 SP - 4 EP - 9 PY - 2020 ER -

Science Communicator Platform

Authors

Abstract